Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RESEARCH TRIANGLE PARK, N.C., AUG. 05, 2026 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS SECOND QUARTER 2026 FINANCIAL RESULTS BEFORE THE OPENING OF THE U.S. FINANCIAL MARKETS ON TUESDAY, AUGUST 11, 2026. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST THAT DAY TO DISCUSS THE COMPANY'S FINANCIAL AND BUSINESS RESULTS.

FENNEC PHARMACEUTICALS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ONAUGUST 11, 2026

RESEARCH TRIANGLE PARK, N.C., JUNE 22, 2026 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON JUNE 10, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF INCENTIVE STOCK OPTION AWARDS (ISOS) TO PURCHASE AN AGGREGATE OF 15,000 OF THE COMPANY'S COMMON SHARES TO ONE NEW NON-EXECUTIVE EMPLOYEE OF THE COMPANY WITH A GRANT DATE OF JUNE 22, 2026 UNDER THE COMPANY'S 2026 EQUITY INDUCEMENT PLAN (THE INDUCEMENT PLAN). THE ISOS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEE ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

FENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., JUNE 15, 2026 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON JUNE 10, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF INCENTIVE STOCK OPTION AWARDS (ISOS) TO PURCHASE AN AGGREGATE OF 10,000 OF THE COMPANY'S COMMON SHARES TO ONE NEW NON-EXECUTIVE EMPLOYEE OF THE COMPANY WITH A GRANT DATE OF JUNE 15, 2026 UNDER THE COMPANY'S 2026 EQUITY INDUCEMENT PLAN (THE INDUCEMENT PLAN). THE ISOS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEE ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

RESEARCH TRIANGLE PARK, N.C., JUNE 10, 2026 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (THE COMPANY) (NASDAQ:FENC) (TSX:FRX) TODAY ANNOUNCED THAT THE NOMINEES LISTED IN THE MANAGEMENT PROXY CIRCULAR DATED APRIL 28, 2026 WERE ELECTED AS DIRECTORS OF THE COMPANY AT THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS HELD ONLINE ON JUNE 10, 2025.

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

~ GROWING INDEPENDENT RESEARCH EFFORTS ARE EXPANDING EVIDENCE BASE AROUND HOW PEDMARK  (SODIUM THIOSULFATE INJECTION) MAY BENEFIT BROADER AND MORE DIVERSE PATIENT POPULATIONS ~

FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH SUPPORTING INTEGRATION AND USE OF PEDMARK AT THE 2026 ASCO ANNUAL MEETING

RESEARCH TRIANGLE PARK, N.C., MAY 18, 2026 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON MAY 11, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF STOCK OPTION AWARDS (STOCK OPTIONS) TO PURCHASE AN AGGREGATE OF 50,000 OF THE COMPANY'S COMMON SHARES TO THREE NEW NON-EXECUTIVE EMPLOYEES OF THE COMPANY WITH A GRANT DATE OF MAY 18, 2026 UNDER THE COMPANY'S 2026 EQUITY INDUCEMENT PLAN (THE INDUCEMENT PLAN). THE STOCK OPTIONS CONSIST OF INCENTIVE STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 49,141 SHARES AND NONQUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 859 SHARES. THE STOCK OPTIONS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

~ ACHIEVED FIRST QUARTER 2026 TOTAL NET REVENUES OF $15.1 MILLION, UP 73% YEAR OVER YEAR ~ ~ FIELD SALES EXPANSION SHOWING EARLY SIGNS OF POSITIVE RESULTS WITH RECORD PEDMARK  DEMAND IN APRIL 2026 ~ ~ INITIATED THIRD INSTITUTION-LED CLINICAL STUDY EVALUATING PEDMARK  IN ADOLESCENT AND YOUNG ADULT (AYA) AND ADULT PATIENTS WITH HEAD AND NECK AND TESTICULAR CANCERS ~ ~ FOUR ABSTRACTS EVALUATING PEDMARK  WILL BE INCLUDED IN THE UPCOMING 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING PROGRAM ~ ~ MANAGEMENT TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. ET ~ RESEARCH TRIANGLE PARK, N.C.

FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

RESEARCH TRIANGLE PARK, N.C., MAY 07, 2026 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS FIRST QUARTER 2026 FINANCIAL RESULTS BEFORE THE OPENING OF THE U.S. FINANCIAL MARKETS ON THURSDAY, MAY 14, 2026. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST THAT DAY TO DISCUSS THE COMPANY'S FINANCIAL AND BUSINESS RESULTS.

FENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ONMAY 14, 2026

TAIPEI, MAY 6, 2026 /PRNEWSWIRE/ -- FAR EASTERN NEW CENTURY CORPORATION ("FENC" OR "THE COMPANY") HAS ONCE AGAIN BEEN SELECTED AS A CONSTITUENT OF S&P GLOBAL 2026 DOW JONES BEST IN CLASS (DJBIC) EMERGING MARKETS INDEX, STANDING OUT AMONG APPROXIMATELY 3,500 INVITED COMPANIES WORLDWIDE. THIS MARKS THE SECOND CONSECUTIVE YEAR THAT FENC HAS BEEN INCLUDED IN THE INDEX, UNDERSCORING THE COMPANY'S SOLID PERFORMANCE IN SUSTAINABILITY PRACTICES AND RISK MANAGEMENT CAPABILITIES.

FENC SECURES SECOND CONSECUTIVE INCLUSION IN S&P GLOBAL DOW JONES BEST IN CLASS EMERGING MARKETS INDEX

~ UNIVERSITY OF ARIZONA CANCER CENTER INITIATING STUDY TO EXPLORE USE OF PEDMARK  IN AYA & ADULT PATIENTS WITH SOLID TUMORS RECEIVING CISPLATIN ~

Fennec Pharmaceuticals Inc.

FENC

Price

Financial Reports

No items found.

Press Releases

Fennec Pharmaceuticals Inc.

FENC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

FENC